{
    "clinical_study": {
        "@rank": "94245", 
        "arm_group": [
            {
                "arm_group_label": "AMG 232, Trametinib, Dabrabenib", 
                "arm_group_type": "Experimental", 
                "description": "Part 1 and 2 arm 1 and Part 3"
            }, 
            {
                "arm_group_label": "AMG 232, Trametinib", 
                "arm_group_type": "Experimental", 
                "description": "Part 1 and 2 arm 2"
            }, 
            {
                "arm_group_label": "Trametinib and Dabrafenib", 
                "arm_group_type": "Active Comparator", 
                "description": "Part 3"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 1b/2a, open-label, sequential dose escalation, expansion study of AMG 232 in subjects\n      with metastatic melanoma followed by a direct comparison of AMG 232, trametinib, and\n      dabrafenib versus trametinib and dabrafenib alone."
        }, 
        "brief_title": "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma", 
        "completion_date": {
            "#text": "April 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Malignancy", 
            "Advanced Solid Tumors", 
            "Cancer", 
            "Oncology", 
            "Oncology Patients", 
            "Tumors", 
            "Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have histologically or cytologically confirmed metastatic cutaneous\n             melanoma\n\n          -  Able to swallow and retain orally administered medicaiton\n\n          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments\n\n        Exclusion Criteria:\n\n          -  Clinically significant bleeding within 4 weeks of screening\n\n          -  Current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors\n\n          -  Infection requiring anti-infective treatments within 1 week of study enrollment\n\n          -  Anti-tumor therapy\n\n          -  Major surgery within 28 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "146", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110355", 
            "org_study_id": "20120238"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AMG 232, Trametinib, Dabrabenib", 
                    "AMG 232, Trametinib"
                ], 
                "description": "Given as an oral tablet in escalating doses", 
                "intervention_name": "AMG 232", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "AMG 232, Trametinib, Dabrabenib", 
                    "AMG 232, Trametinib", 
                    "Trametinib and Dabrafenib"
                ], 
                "description": "Trametinib is an anti-cancer agent", 
                "intervention_name": "Trametinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "AMG 232, Trametinib, Dabrabenib", 
                    "Trametinib and Dabrafenib"
                ], 
                "description": "Dabrafenib is an anti-cancer agent", 
                "intervention_name": "Dabrafenib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Metastatic melanoma", 
        "lastchanged_date": "April 8, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subject incidence of adverse events, dose limiting toxicities, and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110355"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1", 
            "measure": "Objective Tumor Response", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}